THE FEATURES OE CLINICAL AND LABORATORY DIAGNOSIS OF FABRY DISEASE

  • N O. Pichkur Центр орфанних захворювань НДСЛ «Охматдит» МОЗ України
Keywords: Fabry disease, GLA gene, –galactosidase A, DNA diagnostics, screening

Abstract

The aim of the study was to determine the clinical features and molecular genetic patterns of patients with Fabry disease (FD) to optimize the diagnostic stepwise.

Object and methods. The comparison of clinical features was performed and the activity of lysosomal enzyme a–galactosidase A in the peripheral blood leukocyte homogenate was studied in 120 male with the neuropathic pain or acroparesthesia who contacted the Center of Orphan Diseases of NSCH “Ohmatdyt” in years 2002–2016. The cascade family screening (in 8 people) at low enzyme levels and molecular genetic analysis for the presence of mutations in the GLA gene were performed.

Results. The activity of –galactosidase A was decreased (range 0.5–12.6 nM/mg/h with median 2.0 nM/mg/h) in nine cases (7.5%). All these patients had additional clinical signs (angiokeratoma, hypertrophic cardiomyopathy, coarse facial features, and compromised family tree). The diagnosis of FD were confirmed by the molecular genetic analysis in the GLA gene; there were identified two new mutations (p.739 740delAA and C.945 946delinsTTGA). The other mutations in 6 out of 8 examined families were revealed by the screening of the first kinship degree female relatives, but the activity of –galactosidase A in leukocytes was only reduced in 4 of them.

Conclusion. The multisystem lesions and the difference in the clinical signs of FD complicate the timely formulation of diagnosis. Selective screening among patients with renal insufficiency, cardiac pathology, and ischemic stroke in the anamnesis increases the possibility of FD diagnosis. Cascade family screening of FD patients relatives is highly effective in identification new patients with non–classical form of FD. Inclusion in the selective group of persons with chronic diseases, compromised pedigree, acroparesthesia and additional FD probable clinical signs reduces the range ofpatients for further high–cost testing and optimizes the diagnosis of FD.

Downloads

Download data is not yet available.

References

Burlina A. The Central Nervous System Involvement in Fabry Disease. A Review / A. Burlina, J. Politei // J. Inborn Errors of Metabolism and Screening. – 2016. – Vol. 4. – P. 1–7.

Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry / R. J. Hopkin, J. Bissler, M. Banikazemi [et al.] // Pediatr. Res. – 2008. – Vol. 64. – P. 550–555.

Disease manifestations and X inactivation in heterozygous females with Fabry disease / E. M. Maier, S. Osterrieder, C. Whybra [et al.] // Acta Paediatr. Suppl. – 2006. – Vol. 95. – P. 30–38.

End–stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry / A. Ortiz, B. Cianciaruso, M. Cizmarik [et al.] // NDT. – 2010. – Vol. 25. – P. 769–775.

Fabry disease: Identification of 50 novel a–galactosidase A mutations causing the classic phenotype and three–dimensional structural analysis of 29 missense mutations / J. Shabbeer, M. Yasuda, S. D Benson, R. J. Desnick // Hum. Genomics. – 2006. – Vol. 2. – P. 297–309.

Fabry disease in children: a federal screening programme in Russia / L. S. Namazova–Baranova, A. A. Baranov, A. A. Pushkov, K. V. Savostyanov // Eur. J. Pediatr. – 2017. – Vol. 176. – P. 1385–1391.

Genetic screening of Anderson–Fabry disease in probands referred from multispecialty clinics / V. Favalli, E. Disabella, M. Molinaro [et al.] // J. Amer. College Card. – 2016. – Vol. 68. – P. 1037–1050.

High incidence of later–onset Fabry disease revealed by newborn screening / M. Spada, S. Pagliardini, M. Yasuda [et al.] // Am. J. Hum. Genet. – 2006. – Vol. 79. – P. 31–40.

High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population / H. Y. Lin, K. W. Chong, J. H. Hsu [et al.] // Circ. Cardiovasc. Genet. – 2009. – Vol. 2. – P. 450–456.

Human Gene Mutation Data base [Internet]. – Available from: http://www.hgmd.cf.ac.uk/Fabry.

Lysosomal storage disorders. A practical guide / ed. A. Mehta, B. Winchester. – Hoboken: Wiley– Blackwell, 2012. – 58 p.

Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta–analysis: effectiveness of ERT in different disease stages / S. M. Rombach, B. E. Smid, G. E. Linthorst [et al.] // J. Inherit. Metab. Dis. – 2014. – Vol. 37. – P. 341–352.

Newborn screening for Fabry disease in the north–west of Spain / C. Colon, S. Ortolano, C. Melcon–Crespo [et al.] / / Eur. J. Pediatr. – 2017. – Vol. 176. – P. 1075–1081.

Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study / T. Inoue, K. Hattori, K. Ihara [et al.] // J. Hum. Genet. – 2013. – Vol. 58. – P. 548–552.

Pharmacological chaperones as therapeutics for lysosomal storage diseases / R. E. Boyd, G. Lee, P. Rybczynski [et al.] // J. Med. Chem. – 2013. – Vol. 56. . 2705–2725.

Poupëtovâ H. The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations / H. Poupëtovâ, J. Ledvinovâ, L. Bernâ // J. Inherit. Metab. Dis. – 2010. – Vol. 33. – P. 382–396.

Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study / A. Rolfs, T. Bottcher, M. Zschiesche [et al.] // Lancet. – 2005. – Vol. 366. – P. 1794–1796.

Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment / J. M. Politei, D. Bouhassira, D. P. Germain [et al.] // CNS Neurosci. Ther. – 2016. – Vol. 22. – P. 568–576.

Prevalence of lysosomal storage disorders / P. J. Meikle, J. J. Hopwood, A. E. Clague, W. F. Carey // JAMA. – 1999. – Vol. 281. – P. 249–254.

Screening, diagnosis, and management of patients with fabry disease: conclusions from a “Kidney Disease: Improving Global Jutcomes” (KDIGO) controversies conference / R. Schiffmann, D. A. Hughes, G. E. Linthorst [et al.] // Kidney International. – 2017. – Vol. 91. – P. 284–293.

Screening for Fabry disease in patients undergoing dialysis for chronic renal failure in Turkey: Identification of new case with novel mutation / I. Okur, F. Ezgu, G. Biberoglu [et al.] / Gene. – 2013. – Vol. 527. – P. 42–47.

Suzuki Y. Chaperone therapy update: Fabry disease, GM1–gangliosidosis and Gaucher disease / Y. Suzuki // Brain Dev. – 2013. – Vol. 35. – P. 515–523.

Systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance / L. van der Tol, B. E. Smid, B. J. Poorthuis [et al.] // J. Med. Genet. – 2014. – Vol. 51. – P. 1–9.

Wenger D. A. Screening for lysosomal disorders / D. A. Wenger, C. Williams // In: Techniques in diagnostics of human biochemical genetics: A Laboratory Manual. – NY : Wiley–Liss, 1991. – 646 p.


Abstract views: 305
PDF Downloads: 273
Published
2017-12-08
How to Cite
Pichkur, N. O. (2017). THE FEATURES OE CLINICAL AND LABORATORY DIAGNOSIS OF FABRY DISEASE. Ukrainian Journal of Nephrology and Dialysis, (4(56), 30-36. https://doi.org/10.31450/ukrjnd.4(56).2017.02